Abstract:This study examines the pivotal role of the PD‐1/PD‐L1 immune checkpoint interaction in tumor immunotherapy. Due to the absence of mature small molecule inhibitors in the market, exploring novel PD‐L1 small molecule inhibitors is imperative. Utilizing asymmetric biphenyl compounds developed by BMS Corporation, we assembled 39 small molecule compounds with analogous biphenyl scaffolds from the literature. By employing QSAR methods, these compounds were randomly divided into training and test sets, facilitating the successful construction of CoMFA and CoMSIA models, and thereby laying the groundwork for further research. Extracting insights from the spatial fields depicted in the three‐dimensional contour maps, including the electrostatic field, hydrophobic field, and hydrogen bond donor field, the most active molecule, 37, was selected from the training set. Its specific positions were modified, and functional groups were added to enhance its activity. Based on this, a series of structurally novel and potentially active small molecule compounds (37 a–37 e) were designed. Comprehensive studies were conducted on one of these compounds, 37 c, including molecular docking, molecular dynamics simulations, ADME predictions, and other operations, confirming its closer interaction with the amino acid residues of the PD‐L1 dimer in comparison to 37. This study offers new insights and options for the development of PD‐L1‐based small molecule inhibitors through the application of computational techniques and rational drug design principles. Blocking the interaction between programmed cell death‐1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1) is a crucial immunotherapeutic strategy for cancer. Currently, all inhibitors available on the market that target PD‐1/PD‐L1 are monoclonal antibodies, with no small molecule drugs yet accessible. This study focused on PD‐L1 and conducted three‐dimensional quantitative structure‐activity relationship (3D‐QSAR) research on 39 PD‐L1 inhibitors using Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA). The CoMFA (q2=0.593, r2=0.991) and CoMSIA (q2=0.542, r2=0.971) models were successfully established. Based on these models, a series of structurally novel and potentially active PD‐L1 inhibitors (37 a–37 e) were designed. Among these compounds, 37 c exhibited superior performance, with CoMFA predicting a pIC50 value of 9.204 and CoMSIA predicting a pIC50 value of 8.597. Further molecular docking and molecular dynamics simulations revealed that compound 37 c establishes hydrophobic interactions with BTyr56 and BVal68 of PD‐L1, engages in hydrogen bonds with AAsp122, ALys124, and BTyr123, and forms electrostatic interactions with ALys124 and AMet115. The design of this biphenyl series of inhibitors offers additional options for the development of small molecule inhibitors targeting PD‐L1, with 37 c expected to be a promising inhibitor of PD‐L1.

Place of methotrexate in the treatment of psoriasis in the era of biologic agents

Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, ADMET, and Molecular Dynamics (MD) Simulation of Potential Inhibitors of PD-L1 from the Library of Marine Natural Products

Adhesion and invasion to epithelial cells by fimA genotypes of Porphyromonas gingivalis.

A Computational Approach to Identify Small Molecules Interact with Crystal Structure of Programmed Cell Death Protein 1 as Potential Therapeutics for Cancer Immunotherapy

A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules

An in silico investigation on the binding site preference of PD-1 and PD-L1 for designing antibodies for targeted cancer therapy

Molecular modeling studies of Indoline Scaffold derivatives as PD‐1/PD‐L1 pathway inhibitors by QSAR, molecular docking and molecular dynamics simulation techniques

Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction

Innovative Virtual Screening of PD-L1 Inhibitors: The Synergy of Molecular Similarity, Neural Networks, and GNINA Docking

Design of Biphenyl‐Type Programmed Cell Death‐Ligand 1 Inhibitors Using 3D‐QSAR, Molecular Docking, and Molecular Dynamics Simulation

Computational Approach for the Development of pH-Selective PD-1/PD-L1 Signaling Pathway Inhibition in Fight with Cancer

Computational analysis of PD-L1 dimerization mechanism induced by small molecules and potential dynamical properties

Computational identification of PDL1 inhibitors and their cytotoxic effects with silver and gold nanoparticles

Inactive-enriched machine-learning models exploiting patent data improve structure-based virtual screening for PDL1 dimerizers

The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD)

[Modern Treatment of Obstipation].

Identifying Potential Dual Inhibitory Candidates for Non-Small Cell Lung Cancer Through Molecular Docking, 3D-QSAR Pharmacophore-based Virtual Screening, Comparative Molecular Field and Similarity Indices Analysis Modeling

Theoretical investigation on QSAR of (2-Methyl-3-biphenylyl) methanol analogs as PD-L1 inhibitor

QSAR Pharmacophore-based Virtual Screening, CoMFA and CoMSIA Modeling and Molecular Docking towards Identifying Lead Compounds for Breast Cancer Protease Inhibitors

Computational insights into inhibiting EphA2: Integrating structure-based virtual screening, docking, and molecular dynamics simulations for small molecule discovery

Towards novel small-molecule inhibitors blocking PD-1/PD-L1 pathway: From explainable machine learning models to molecular dynamics simulation